Merck + Co., Inc.

Edward J Metzger

Soumya P Sahoo

Victoria K Lombardo

Hiroo Koyama

Ranjit C Desai

Jeffrey P Bergman

James V Heck

Conrad Santini

Julia K Boueres

Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.

Arylthiazolidinedione derivatives

Substituted 5-aryl-2,4-thiazolidinediones or 5-aryl-2,4-oxazolidinediones that also carry a second substituent in the 5-position of the heterocyclic ring are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr;, &dgr; and/or &ggr; mediated diseases, disorders and conditions.

Arylthiazolidinedione and aryloxazolidinedione derivatives

Growing community of inventors

Edison, NJ, United States of America

Edward J Metzger